MX2009006696A - Tratamiento de diabetes con al menos un anticuerpo especifico del receptor del factor de crecimiento epidermico o uin derivado de este. - Google Patents

Tratamiento de diabetes con al menos un anticuerpo especifico del receptor del factor de crecimiento epidermico o uin derivado de este.

Info

Publication number
MX2009006696A
MX2009006696A MX2009006696A MX2009006696A MX2009006696A MX 2009006696 A MX2009006696 A MX 2009006696A MX 2009006696 A MX2009006696 A MX 2009006696A MX 2009006696 A MX2009006696 A MX 2009006696A MX 2009006696 A MX2009006696 A MX 2009006696A
Authority
MX
Mexico
Prior art keywords
diabetes
derivative
treatment
growth factor
specific antibody
Prior art date
Application number
MX2009006696A
Other languages
English (en)
Inventor
Edgar Selzer
Gabriela Kornek
Original Assignee
Novelix Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novelix Therapeutics Gmbh filed Critical Novelix Therapeutics Gmbh
Publication of MX2009006696A publication Critical patent/MX2009006696A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con el uso al menos de un anticuerpo específico del factor de crecimiento epidérmico o un derivado de este para la elaboración de un medicamento para el tratamiento de la diabetes, en particular de diabetes mellitus en etapa avanzada dependiente de insulina del tipo 1 y 2 en humanos así como en animales.
MX2009006696A 2006-12-22 2007-12-21 Tratamiento de diabetes con al menos un anticuerpo especifico del receptor del factor de crecimiento epidermico o uin derivado de este. MX2009006696A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT21352006 2006-12-22
PCT/AT2007/000584 WO2008077171A1 (en) 2006-12-22 2007-12-21 Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof

Publications (1)

Publication Number Publication Date
MX2009006696A true MX2009006696A (es) 2009-06-30

Family

ID=39171350

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006696A MX2009006696A (es) 2006-12-22 2007-12-21 Tratamiento de diabetes con al menos un anticuerpo especifico del receptor del factor de crecimiento epidermico o uin derivado de este.

Country Status (9)

Country Link
US (1) US20100034816A1 (es)
EP (1) EP2094303A1 (es)
JP (1) JP2010513321A (es)
CN (1) CN101605561A (es)
CA (1) CA2671585A1 (es)
IL (1) IL198997A0 (es)
MX (1) MX2009006696A (es)
RU (1) RU2009128237A (es)
WO (1) WO2008077171A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107522785B (zh) * 2016-06-22 2020-05-08 北京大学 抗egfr突变体iii单克隆抗体、制备方法及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
EP1362868A3 (en) * 1991-03-06 2004-02-11 MERCK PATENT GmbH Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP0625200B1 (en) * 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
MX9504802A (es) * 1994-03-17 1997-05-31 Merck Patent Gmbh Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
ATE208403T1 (de) * 1995-05-26 2001-11-15 Merck Patent Gmbh Antiidiotypische antikörper die eine immunantwort gegen den rezeptor für epidermalen wachstumsfaktor induzieren
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
CA2368017A1 (en) 1999-04-06 2000-10-12 Genentech, Inc. Use of erbb receptor ligands in treating diabetes
US6291496B1 (en) * 1999-12-27 2001-09-18 Andrew J. Dannenberg Treating cancers associated with overexpression of class I family of receptor tyrosine kinases
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
CN100488563C (zh) * 2001-02-19 2009-05-20 默克专利有限公司 免疫原性降低的经修饰抗egfr抗体
WO2005011592A2 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indazole-o-glucosides
US7659284B2 (en) * 2004-09-15 2010-02-09 Janssen Pharmaceutica Nv Thiazolopyridine kinase inhibitors
WO2006128125A2 (en) * 2005-05-27 2006-11-30 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
WO2007011702A2 (en) * 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Use of egfr inhibitors to prevent or treat obesity
US7723484B2 (en) * 2005-11-12 2010-05-25 Applied Molecular Evolution, Inc. Anti-EGFR antibodies

Also Published As

Publication number Publication date
US20100034816A1 (en) 2010-02-11
IL198997A0 (en) 2011-08-01
EP2094303A1 (en) 2009-09-02
RU2009128237A (ru) 2011-01-27
WO2008077171A1 (en) 2008-07-03
CA2671585A1 (en) 2008-07-03
CN101605561A (zh) 2009-12-16
JP2010513321A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
GEP20135803B (en) Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
SG135192A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
WO2005074607A3 (en) Method of treating hemolytic disease
WO2006108670A3 (en) Use of cd25 antibodies in immunotherapy
WO2007020502A3 (en) Cannabinoid receptor ligands and uses thereof
WO2007025977A3 (en) Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
MY148483A (en) 4,5-diphenyl-pyrimidinyl-oxy or-mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
IN2012DN01531A (es)
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
UA92894C2 (ru) Способ приготовления и применения композиции адсорбента фосфата, адсорбент фосфата, композиция адсорбента фосфата
HK1097774A1 (en) Stable pharmaceutical composition comprising linezolid from iv
RU2012157473A (ru) Способ выявления или лечения реакции "трансплантат против хозяина"
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
WO2007098964A3 (en) Pyrrazole derivatives as sigma receptors antagonists
WO2009115252A3 (de) Substituierte pyrazolamide und ihre verwendung
WO2007009686A3 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
MY140538A (en) Substituted n-acyl-2-aminothiazoles
WO2006080043A3 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
WO2010025135A3 (en) Trimeprazine and ethopropazine derivatives for promoting bone growth
MX2009006696A (es) Tratamiento de diabetes con al menos un anticuerpo especifico del receptor del factor de crecimiento epidermico o uin derivado de este.
WO2009037586A3 (en) Use of peptidic vasopressin receptor agonists